Image

Attention and Eye Movement in Parkinson's Disease

Attention and Eye Movement in Parkinson's Disease

Recruiting
19-90 years
All
Phase N/A

Powered by AI

Overview

The goal of this observational and interventional study is to understand how therapeutic deep brain stimulation (DBS) affects attention, perception and cognition in participants with Parkinson's disease (PD) and essential tremor (ET). The main questions it aims to answer are:

  • Does impaired control of attention and eye movement in PD alter how social cues are perceived and interpreted?
  • Does therapeutic DBS improve or worsen attentional and perceptual deficits for social cues in PD and ET?
  • Can DBS be optimized to restore normal attentional control in PD while remaining an effective therapy for other aspects of the disorder.
  • What do parts of the brain targeted by DBS contribute to the control of attention?

Using an eye tracking camera, investigators will study how participants with PD and ET look at and perceive facial expressions of emotion before and after starting DBS therapy, in comparison to a group of healthy participants without ET, PD or DBS. Participants with PD and ET will see and rate morphed facial expressions on a computer screen in three conditions:

  • Before starting DBS therapy (over approximately 1 hour).
  • In the operating room, during the standard procedure to implant DBS electrodes, while the participant is awake (for no more than 15 minutes).
  • After starting DBS therapy, with brief experimental changes of DBS stimulation level and frequency (over approximately 1 hour).

Description

Parkinson's disease (PD) is the second most common age-related neurodegenerative disorder, with approximately 90,000 new cases diagnosed annually in North America. Although motor symptoms define the disorder, PD also leads to cognitive and emotional changes, such as difficulties in recognizing facial expressions and regulating attention, which often overshadow motor issues as the disease progresses. The goal of this study is to better understand the link between attention, eye movement, and emotional perception in PD, testing the hypothesis that disrupted attention leads to altered perception of facial emotions. The study will also investigate how deep brain stimulation (DBS) of the subthalamic nucleus (STN) affects these processes, providing critical insights into the cognitive and perceptual consequences of the treatment.

This research addresses a critical gap in understanding non-motor symptoms of Parkinson's disease by exploring how attention, eye movement, and perception interact. Findings will provide evidence on whether cognitive and emotional symptoms in PD stem from impaired attentional control, offering a new framework for treating these deficits. Additionally, the study will shed light on how different DBS frequencies affect perception and cognition, potentially guiding personalized stimulation strategies to alleviate both motor and non-motor symptoms. The insights gained may influence future therapies for PD, advancing both scientific knowledge and patient care.

Participants will be divided into three groups: PD undergoing DBS, essential tremor (ET) undergoing DBS (as a comparison group for non-PD DBS effects) and healthy age- and sex-matched controls. Participants will complete facial morph rating tasks (rating faces as happy, neutral, or sad) and visual search tasks (finding faces among distractors), while their eye movements are tracked.

The first study aim is to measure how altered attention influences facial emotion perception in PD by tracking eye movements while participants view and categorize emotional face stimuli. The second aim is to characterize brain activity in the STN related to attentional and perceptual processes during awake DBS surgery by capturing microelectrode recordings (MER) of neural activity while participants view emotional faces, allowing researchers to map STN's role in guiding attention and eye movements. The third aim is to test how DBS stimulation at different frequencies (high, low, or off) affects attention, eye movement, and emotional perception by having participants perform visual and perceptual tasks under varying DBS settings to evaluate how brain stimulation influences cognitive and perceptual functions.

Eligibility

Inclusion Criteria

  • All Participants (Aim 1):
    • Ability and willingness to provide signed informed consent for this study
    • Ability to express perceptual judgments through a button press or mouse- controlled computerized slider
    • Age 19 - 90 years
  • DBS Participants (Aim 1):
    • Diagnosis of idiopathic Parkinson's disease (PD) or essential tremor (ET)
    • Scheduled for new implantation of a therapeutic DBS device targeted to subthalamic nucleus (STN), ventral intermediate nucleus of thalamus (VIM) or internal globus pallidus (GPi)
  • Comparison Participants (Aim 1):
    • Selection by age matching to participants in PD group
  • Parkinson's disease (PD) and essential tremor (ET) Participants (Aim 2):
    • Ability and willingness to provide signed informed consent for this study
    • Ability to express perceptual judgments through a button press or mouse- controlled computerized slider
    • Age 19 - 90 years
    • Scheduled for awake DBS implantation with clinical micro-electrode recordings (MER)
    • Willing and able to engage in tasks during an awake surgical procedure
  • Parkinson's disease (PD) and essential tremor (ET) Participants (Aim 3):
    • Ability and willingness to provide signed informed consent for this study
    • Ability to express perceptual judgments through a button press or mouse- controlled computerized slider
    • Age 19 - 90 years
    • Willing to undergo acute manipulations of DBS
    • Able to tolerate acute changes of DBS

Exclusion Criteria

  • All Participants (Aim 1):
    • Corrected visual acuity insufficient to perceptually judge face stimuli
    • Inability to understand task instructions or complete task requirements
  • DBS Participants (Aim 1):
    • Insufficient therapeutic control of motor symptoms to engage in tasks requiring button press or use of a mouse to control a slider
  • Healthy Comparison Participants (Aim 1):
    • History of neurodegenerative disorder
  • Parkinson's disease (PD) and essential tremor (ET) Participants (Aim 2):
    • Corrected visual acuity insufficient to perceptually judge face stimuli
    • Inability to understand task instructions or complete task requirements
    • Not undergoing awake DBS implantation
    • Uncorrected visual acuity insufficient to perceptually judge face stimuli
  • Parkinson's disease (PD) and essential tremor (ET) Participants (Aim 3):
    • Corrected visual acuity insufficient to perceptually judge face stimuli
    • Inability to understand task instructions or complete task requirements
    • Failure of DBS to achieve a therapeutic effect on motor symptoms

Study details
    Essential Tremor
    Parkinson's Disease (PD)

NCT06899022

University of Nebraska

31 January 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.